“…Similar findings were also reported in other organs, including the uterus [81][82][83][84][85], colorectum [86], ovaries [23], esophagus [87,88], breasts [89,90], gallbladder [91], nasopharynx [92,93], stomach [74,94], lungs [95], and pancreas [96]. In urogenital organs, too, recent studies have demonstrated that serum GGT can predict survival in patients with advanced GU cancer, including RCC [11,12], PC [13], and UC [14]. Thus, it can be speculated that serum GGT has the potential to become a general biomarker of the tumor burden in patients with GU cancer, given that tumors arising from the urogenital organs overexpress GGT [46], possibly leading to its release into the bloodstream and its presence in the serum of patients with a metastatic disease in particular.…”